Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alverine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | FDPS | P14324 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alverine SCHEMBL29362952 | 0.84 | LMNA (0.73) | KDM4ELMNACYP1A2CYP2D6MEN1 | |
| Alverine SCHEMBL5059354 | 0.83 | KCNH2 (0.85) | KDM4ELMNACYP1A2CYP2D6MEN1 | |
| Alverine SCHEMBL5059400 | 0.82 | KCNH2 (0.82) | KDM4ELMNACYP1A2CYP2D6MEN1 | |
| Alverine SCHEMBL5059384 | 0.82 | KCNH2 (0.82) | KDM4ELMNACYP1A2CYP2D6MEN1 | |
| Citric Acid SCHEMBL10409457 | 0.82 | KDM4E (0.68) | KDM4ELMNACYP1A2CYP2D6MEN1 | |
| Citric Acid SCHEMBL10410536 | 0.82 | CYP1A2 (0.68) | KDM4ELMNACYP1A2CYP2D6MEN1 | |
| Citric Acid SCHEMBL28146953 | 0.81 | KDM4E (0.68) | KDM4ELMNACYP1A2CYP2D6MEN1 | |
| Citric Acid SCHEMBL29406537 | 0.81 | KDM4E (0.68) | KDM4ELMNACYP1A2CYP2D6MEN1 | |
| SCHEMBL5711715 | 0.81 | KCNH2 (0.74) | KDM4ELMNACYP1A2CYP2D6MEN1 | |
| Citric Acid SCHEMBL8151041 | 0.81 | LMNA (0.67) | KDM4ELMNACYP1A2CYP2D6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 583 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094666-A | Pharmaceutical composition comprising simethicone and alverine citrate, pharmaceutical composition comprising simethicone, pharmaceutical composition comprising alverine citrate and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-119684133-A | Purification method of alverine citrate intermediate | 浙江车头制药股份有限公司 | 2025-03-25 | — | — | CN | claimed |
| US-20250090501-A1 | METHODS OF TREATING GUT MOTILITY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-20 | — | — | US | claimed |
| EP-4460293-A2 | METHODS OF TREATING GUT MOTILITY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-13 | — | — | EP | claimed |
| WO-2024028324-A1 | MOLECULES FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISORDERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-02-08 | — | — | WO | claimed |
| US-20230310348-A1 | USE OF ALVERINE OR ITS DERIVATIVES FOR THE TREATMENT OF MITOCHONDRIAL DISEASES OR DYSFUNCTION ASSOCIATED WITH MITOCHONDRIAL COMPLEX I DEFICIENCIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-10-05 | — | — | US | claimed |
| US-20230270828-A1 | COMPOSITION FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | BICT S.R.L. (IT) | 2023-08-31 | — | — | US | claimed |
| WO-2023130149-A2 | METHODS OF TREATING GUT MOTILITY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | claimed |
| CN-116249523-A | Alverine or derivatives thereof for the treatment of mitochondrial diseases or disorders associated with mitochondrial complex I deficiencies | 法国抗肌病协会 | 2023-06-09 | — | — | CN | claimed |
| EP-4185377-A1 | USE OF ALVERINE OR ITS DERIVATIVES FOR THE TREATMENT OF MITOCHONDRIAL DISEASES OR DYSFUNCTION ASSOCIATED WITH MITOCHONDRIAL COMPLEX I DEFICIENCIES | Association Française contre les Myopathies (FR) | 2023-05-31 | — | — | EP | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-2165704-B1 | Use of alverine for the treatment of cutaneous affections | FAURAN FRANCOIS (CH) | 2012-04-18 | — | — | EP | claimed |
| WO-2011107749-A2 | PULSATILE DRUG RELEASE | UNIVERSITY OF STRATHCLYDE (GB) | 2011-09-09 | — | — | WO | claimed |
| WO-2011107750-A2 | DELAYED PROLONGED DRUG DELIVERY | UNIVERSITY OF STRATHCLYDE (GB) | 2011-09-09 | — | — | WO | claimed |
| WO-2011107755-A2 | IMMEDIATE/DELAYED DRUG DELIVERY | UNIVERSITY OF STRATHCLYDE (GB) | 2011-09-09 | — | — | WO | claimed |
| CN-101838205-A | New method for preparing alverine citrate | CHONGQING BEIBEI RES INST OF MODERN APPLIED MEDICINES | 2010-09-22 | — | — | CN | claimed |
| CN-101766588-A | Method for preparing stable simethicone/alverine combination | FRANCE GP PHARMACEUTICAL FACTO | 2010-07-07 | — | — | CN | claimed |
| EP-1904020-A2 | NEW SLIMMING COSMETIC COMPOSITIONS | Sederma S.A.S. (FR) | 2008-04-02 | — | — | EP | claimed |
| WO-2007010478-A2 | SLIMMING COSMETIC COMPOSITIONS | SEDERMA (FR) | 2007-01-25 | — | — | WO | claimed |
| US-6335368-B1 | ADMINISTERING ALVERINE OR SALT COSMETIC TO SKIN AS MUSCLE RELAXANT; AGING RESISTANCE | SOCIETE L'OREAL S.A. (FR) | 2002-01-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090501-A1 | METHODS OF TREATING GUT MOTILITY DISORDERS | SI, SLC10A2, FABP2 | HTR1A 184/4885KDM4E 4541/4885LMNA 3490/4885 |
| US-20230310348-A1 | USE OF ALVERINE OR ITS DERIVATIVES FOR THE TREATMENT OF MITOCHONDRIAL DISEASES OR DYSFUNCTION ASSOCIATED WITH MITOCHONDRIAL COMPLEX I DEFICIENCIES | ACAD9, NDUFAF1, UQCRC1 | HTR1A 3685/4885KDM4E 4498/4885LMNA 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.